447 related articles for article (PubMed ID: 15111503)
1. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
[TBL] [Abstract][Full Text] [Related]
2. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
3. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
4. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
Flock G; Baggio LL; Longuet C; Drucker DJ
Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
6. Incretin hormone receptors are required for normal beta cell development and function in female mice.
Omar B; Ahlkvist L; Yamada Y; Seino Y; Ahrén B
Peptides; 2016 May; 79():58-65. PubMed ID: 27020250
[TBL] [Abstract][Full Text] [Related]
7. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
8. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.
Hansotia T; Maida A; Flock G; Yamada Y; Tsukiyama K; Seino Y; Drucker DJ
J Clin Invest; 2007 Jan; 117(1):143-52. PubMed ID: 17187081
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
11. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
Flock G; Holland D; Seino Y; Drucker DJ
Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
[TBL] [Abstract][Full Text] [Related]
12. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
13. Insulin action in the double incretin receptor knockout mouse.
Ayala JE; Bracy DP; Hansotia T; Flock G; Seino Y; Wasserman DH; Drucker DJ
Diabetes; 2008 Feb; 57(2):288-97. PubMed ID: 17977951
[TBL] [Abstract][Full Text] [Related]
14. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
15. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
16. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
[TBL] [Abstract][Full Text] [Related]
17. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
Li Y; Cao X; Li LX; Brubaker PL; Edlund H; Drucker DJ
Diabetes; 2005 Feb; 54(2):482-91. PubMed ID: 15677506
[TBL] [Abstract][Full Text] [Related]
18. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.
Lamont BJ; Drucker DJ
Diabetes; 2008 Jan; 57(1):190-8. PubMed ID: 17928394
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ
Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
[TBL] [Abstract][Full Text] [Related]
20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
